Nanoscope's MOGENRY® Nears Japanese Approval with Priority Review…

Event summary

PMDA accepted Nanoscope's NDA for MOGENRY® and granted priority review for treating inherited retinal dystrophies (IRDs) in Japan.
MOGENRY® is the first disease-agnostic therapy for IRDs, supported by positive Phase 2b/3 RESTORE and STARLIGHT trial data.
Priority review under Sakigake Designation aims to expedite regulatory decision, with potential approvals in Japan and the U.S. expected in early 2027.
MOGENRY® is a one-time, in-office optogenetic gene therapy designed to restore vision without genetic testing or surgery.

The big picture

Nanoscope's MOGENRY® represents a significant advancement in treating inherited retinal dystrophies, offering a disease-agnostic solution in a space dominated by gene-specific therapies. The PMDA's priority review underscores the urgency and potential of this innovative approach, which could redefine treatment paradigms for IRDs. If approved, MOGENRY® would be the first of its kind in Japan, addressing a critical unmet need for patients with no current treatment options.

What we're watching

Regulatory Momentum: Whether the PMDA's priority review will lead to expedited approval in Japan, potentially setting a precedent for other markets.
Market Expansion: The pace at which Nanoscope can secure approvals in additional regions, given the simultaneous reviews in Japan and the U.S.
Commercialization Strategy: How Nanoscope plans to scale manufacturing and distribution to meet potential demand if MOGENRY® gains approval.